WOBURN, Mass., March 28, 2017 /PRNewswire/ -- Medicinal Genomics (MGC) and Courtagen Life Sciences today are
"The Black Ghiandola" is a zombie-horror adventure with Anthony playing the leading role. The film was made possible thanks to the Make A Film Foundation a nonprofit organization that grants film wishes to children with serious or life-threatening medical conditions by teaming them with noted actors, writers, directors, and producers who help them to create short film legacies.
The film is the foundation's fourth and includes many Hollywood stars who volunteered, including actors Johnny Depp, J.K. Simmons, David Lynch, Laura Dern, Penelope Ann Miller, and Richard Chamberlain, and directors Ted Melfi ("Hidden Figures"), Sam Raimi ("Spider-Man" trilogy), and Catherine Hardwicke ("Twilight"). Anthony's writing partners/mentors included Scott Kosar ("Texas Chainsaw Massacre") and Wash Westmoreland ("Still Alice").
The red-carpet event and screening will provide an opportunity for Anthony's friends and family in the Boston area to view his creation on the big screen and celebrate his life, along with members of the film's cast and crew. Actor Keith Allan ("Z Nation") will make an appearance; and Make A Film Foundation founder Tamika Lamison will introduce the film and host a Q&A session following the screening.
Tickets to the event are free for CannMed Conference attendees. The general public is welcome and can purchase tickets for a donation of $20 or more (adult), or $10 or more (youth/student) through the Make A Film Foundation Ticket Site.
Make a Film Foundation is a 501(c)3 organization that is run entirely by volunteers and financed by donations and in-kind services. Donations to help cover the finishing costs for the film can be made directly to the Make A Film Foundation or via their GoFundMe campaign.
For additional details or to register for CannMed 2017, visit http://www.cannmedevents.com/. Follow on Facebook, Twitter, and Instagram with hashtags #CannMed #CannMed2017.
Editors: Passes are available for accredited media upon request.
About Medicinal Genomics Corporation
Medicinal Genomics Corporation applies state-of-the-art life science technology to cannabis plant genetics, and was the first company to sequence the cannabis genome. Our products, based on Next Generation DNA Sequencing technology, help growers, dispensaries, and safety testing laboratories characterize and understand the quality of medicinal cannabis. Medicinal Genomics is a wholly owned subsidiary of Courtagen Life Sciences, Inc. For more information, please visit http://www.medicinalgenomics.com/
About Courtagen Life Sciences, Inc.
Courtagen Life Sciences, Inc. is a CAP/CLIA certified molecular information company focused on the diagnosis of a range of neurological, endocrine, and functional disorders associated with the central, peripheral, and autonomic nervous systems, including the endocannabinoid receptor system. Courtagen operates a sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business that helps physicians reveal the genotype to phenotype relationships of various diseases, which may be treated with a range of therapies, including pharmaceuticals and medical cannabis. For more information, please visit http://www.courtagen.com/
Contact:Mike CatalanoMedicinal Genomics152413@email4pr.com 877-395-7608
Jennifer Price, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannmed-2017-conference-will-host-red-carpet-event-and-screening-of-film-in-honor-of-local-teen-with-rare-cancer-300430315.html
SOURCE Medicinal Genomics and Courtagen Life Sciences
Subscribe to our Free Newsletters!